Monopar Therapeutics Inc. MNPR
At closeNov 4, 2026, 4:01 PM EST
After hours · Nov 4, 4:01 PM ET
- YTD
- +11.50%
- 1 year
- -11.97%
- Market cap
- 488.71M
- EPS (ttm)
- -2.29
- Shares out
- 5.28M
- Forward P/E
- -10.17
- YTD return
- +11.50%
- 1-year return
- -11.97%
- Volume
- 189.61K
- Avg volume
- 166.50K
- Open
- 70.13
- Previous close
- 69.89
- Day's range
- 70.09 – 74.02
- 52-week range
- 50.12 – 123.84
- Beta
- 1.10
- Price target
- 27.33 (-62.5%)
- Earnings date
- Aug 9, 2024
5D -1.15 (-1.62%)
Key statistics
- Enterprise value
- 48.26M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 12.80
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -4.43M
- Total cash
- 7.12M
- Total debt
- 0
- Return on equity
- -102.31%
- Short % of float
- 10.22%
- 50-day average
- 17.85
- 200-day average
- 7.12
Analyst view
- Target (low)
- 22.00
- Target (mean)
- 27.33
- Target (high)
- 37.00
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 9, 2024
Expected Aug 9, 2024. Consensus EPS estimate -0.42.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -0.46 | -0.37 | +0.09 | +19.57% |
| Aug 9, 2024 | Jun 1, 2024 | -0.45 | -0.50 | -0.05 | -11.11% |
| Aug 9, 2024 | Jun 1, 2024 | -0.45 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.85 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.85 | -0.50 | +0.35 | +41.18% |
| Mar 28, 2024 | Dec 1, 2023 | -0.85 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 14, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| May 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 11, 2024 | JonesTrading | up | Hold | Buy |
| Jun 1, 2023 | HC Wainwright & Co. | reit | — | Buy |
| May 15, 2023 | HC Wainwright & Co. | main | Buy | Buy |
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- monopartx.com
News
Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data 
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145 
Monopar Therapeutics (NASDAQ:MNPR) and Regenicin (OTCMKTS:RGIN) Head-To-Head Contrast 
Monopar Appoints Jeffrey D. Kent, M.D. 
Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy' 
This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday 
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128 
Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119 
Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More - BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133
Your note
Sign in to keep a note on MNPR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERSON RAYMOND WILLIAM | Director | Conversion of Exercise of derivative security | Dec 28, 2023 | 26,863 |
| BROWN MICHAEL J | Director | Conversion of Exercise of derivative security | Dec 28, 2023 | 4,513,800 |
| CITTADINE ANDREW | Chief Operating Officer | Conversion of Exercise of derivative security | Jun 27, 2024 | 193,065 |
| KLAUSNER ARTHUR J | Director | Conversion of Exercise of derivative security | Dec 28, 2023 | 3,086,260 |
| LEO KARL | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 17, 2019 | 0 |
| MAZAR ANDREW PAUL | Officer and Director | Conversion of Exercise of derivative security | Mar 30, 2022 | 4,300,060 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.27% | 14,066 | 337.58K | Sep 29, 2024 |
| Wells Fargo & Company | 0.01% | 500 | 12.00K | Sep 29, 2024 |
| NewEdge Advisors, LLC | 0.01% | 600 | 14.40K | Sep 29, 2024 |
| UBS Group AG | 0.01% | 512 | 12.29K | Sep 29, 2024 |
| Federation Des Caisses Desjardins Du Quebec | 0.00% | 16 | 384 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 13 | 312 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.17% | 9,034 | 216.82K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.17% | 9,024 | 216.58K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.10% | 5,241 | 125.78K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 2,621 | 62.90K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 2,690 | 64.56K | Oct 30, 2024 |